{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:54:07Z","timestamp":1790790847126,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2019PH056"],"award-info":[{"award-number":["ZR2019PH056"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.imlet.2021.11.002","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T22:22:38Z","timestamp":1636669358000},"page":"15-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma"],"prefix":"10.1016","volume":"241","author":[{"given":"Wei","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongfeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.imlet.2021.11.002_bib0001","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advance Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"15","key":"10.1016\/j.imlet.2021.11.002_bib0002","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"6349","key":"10.1016\/j.imlet.2021.11.002_bib0003","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.imlet.2021.11.002_bib0004","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.imlet.2021.11.002_bib0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"A. Ribas, primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.imlet.2021.11.002_bib0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.imlet.2021.11.002_bib0007","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/jcp.29108","article-title":"Transforming growth factor \u03b2 signaling pathway: a promising therapeutic target for cancer","volume":"235","author":"Chen","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.imlet.2021.11.002_bib0008","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/s41375-019-0448-2","article-title":"Transforming growth factor (TGF)-\u03b2 pathway as a therapeutic target in lower risk myelodysplastic syndromes","volume":"33","author":"Bewersdorf","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.imlet.2021.11.002_bib0009","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.imlet.2021.11.002_bib0010","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/path.4832","article-title":"Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy","volume":"241","author":"Liu","year":"2017","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.imlet.2021.11.002_bib0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12943-019-1102-3","article-title":"Harnessing tumor-associated macrophages as aids for cancer immunotherapy","volume":"18","author":"Li","year":"2019","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.imlet.2021.11.002_bib0012","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.imlet.2021.11.002_bib0013","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.imlet.2021.11.002_bib0014","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.imlet.2021.11.002_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1756-0500-4-247","article-title":"Dendritic cells activate and mature after infection with mycobacterium tuberculosis","volume":"4","author":"Mihret","year":"2011","journal-title":"BMC Res. Notes"},{"issue":"1","key":"10.1016\/j.imlet.2021.11.002_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.celrep.2017.12.025","article-title":"A recombinant antibody-expressing influenza virus delays tumor growth in a mouse model","volume":"22","author":"Hamilton","year":"2018","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.imlet.2021.11.002_bib0017","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.imlet.2021.11.002_bib0018","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/1078-0432.CCR-18-2311","article-title":"Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy","volume":"25","author":"Passaro","year":"2019","journal-title":"Clin. Cancer Res. Official J. Am. Association for Cancer Res."},{"issue":"6","key":"10.1016\/j.imlet.2021.11.002_bib0019","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.imlet.2021.11.002_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163768","article-title":"PFK15, a Small Molecule Inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer","volume":"11","author":"Zhu","year":"2016","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.imlet.2021.11.002_bib0021","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1172\/JCI120303","article-title":"Unleashing the therapeutic potential of oncolytic viruses","volume":"128","author":"Bommareddy","year":"2018","journal-title":"J. Clin. Invest"},{"issue":"1","key":"10.1016\/j.imlet.2021.11.002_bib0022","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.imlet.2021.11.002_bib0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.imlet.2021.11.002_bib0024","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/88.2.100","article-title":"Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy","volume":"88","author":"Restifo","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.imlet.2021.11.002_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061699","article-title":"Optimizing oncolytic viral design to enhance antitumor efficacy: progress and challenges","volume":"12","author":"Chaurasiya","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3\u20134","key":"10.1016\/j.imlet.2021.11.002_bib0026","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41417-019-0114-x","article-title":"A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models","volume":"27","author":"Chaurasiya","year":"2020","journal-title":"Cancer Gene. Ther."},{"issue":"2","key":"10.1016\/j.imlet.2021.11.002_bib0027","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2013.220","article-title":"Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies","volume":"22","author":"Workenhe","year":"2014","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.imlet.2021.11.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1220467","article-title":"Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition","volume":"5","author":"Kleinpeter","year":"2016","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.imlet.2021.11.002_bib0029","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s40425-019-0811-x","article-title":"TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma","volume":"7","author":"Reilley","year":"2019","journal-title":"J. Immunother Cancer"},{"issue":"24","key":"10.1016\/j.imlet.2021.11.002_bib0030","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic evolution of T-cell resistance in the course of melanoma progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin. Cancer Res. Official J. Am. Association for Cancer Res."},{"issue":"9","key":"10.1016\/j.imlet.2021.11.002_bib0031","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov."},{"issue":"7528","key":"10.1016\/j.imlet.2021.11.002_bib0032","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.imlet.2021.11.002_bib0033","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"7528","key":"10.1016\/j.imlet.2021.11.002_bib0034","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.imlet.2021.11.002_bib0035","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.it.2019.01.006","article-title":"Neutrophil degranulation, plasticity, and cancer metastasis","volume":"40","author":"Mollinedo","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.imlet.2021.11.002_bib0036","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3389\/fonc.2019.01146","article-title":"Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy","volume":"9","author":"Masucci","year":"2019","journal-title":"Front Oncol."},{"issue":"20","key":"10.1016\/j.imlet.2021.11.002_bib0037","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","article-title":"Neutrophil plasticity in the tumor microenvironment","volume":"133","author":"Giese","year":"2019","journal-title":"Blood"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247821001711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247821001711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:39:50Z","timestamp":1759045190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247821001711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":37,"alternative-id":["S0165247821001711"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2021.11.002","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2021.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}]}}